Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2‐year trial in insulin‐naïve patients with type 2 diabetes. Issue 9 (27th February 2014)

• Record Type: Journal Article
• Authors: Rodbard, H. W.; Cariou, B.; Zinman, B.; Handelsman, Y.; Wolden, M. L.; Rana, A.; Mathieu, C.
• Is Part Of: Diabetes, obesity & metabolism. Volume 16:Issue 9(2014:Sep.)
• Page Start: 869
• Page End: 872
• Publication Date: 2014-02-27
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12271
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12271-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p id="dom12271-para-0001">Insulin degludec (IDeg) is a new basal insulin with an ultra‐long and stable glucose‐lowering effect. We compared once‐daily IDeg and insulin glargine (IGlar), both in combination with metformin ± dipeptidyl peptidase‐4 inhibitors, in a 52‐week, open‐label, treat‐to‐target trial in patients with type 2 diabetes followed by a 52‐week extension trial in which subjects [n = 725/1030 (70.4%)] maintained their initial randomised treatment. Health status was assessed at baseline and 105 weeks using the Short Form‐36 (SF‐36 v2) questionnaire. SF‐36 scores were analysed (ITT population) using <sc>anova</sc>, with adjustments for covariates. At 105 weeks, the overall physical component score was significantly better with IDeg versus IGlar [treatment contrast (TC): 1.1 (0.1; 2.1)_95%_CI, p &lt; 0.05]. This was largely because of significantly better physical functioning [TC: 1.1 (0.0; 2.3)_95%_CI, p &lt; 0.05] and bodily pain sub‐domain scores [TC: 1.5 (0.2; 2.9)_95%_CI, p &lt; 0.05]. Improvements in health status with IDeg compared to IGlar were maintained after 2 years.</p> </abstract>